Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Hematology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ehm.12.32PMID 22992234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.

  2014cited by this paper
• Clonal architecture of secondary acute myeloid leukemia.

  2012cited by this paper
• Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.

  2012cited by this paper
• TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

  2012cited by this paper
• Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

  2012cited by this paper
• Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

  2012cited by this paper
• DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

  2012cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

  2011cited by this paper
• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

  2011cited by this paper
• Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.

  2011cited by this paper
• Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

  2011cited by this paper
• FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

  2011cited by this paper
• Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

  2011cited by this paper
• RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

  2011cited by this paper
• Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

  2011cited by this paper
• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2011cited by this paper
• Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

  2011cited by this paper
• Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

  2011cited by this paper
• Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.

  2011cited by this paper
• Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

  2011cited by this paper
• Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

  2011cited by this paper
• Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.

  2011cited by this paper
• The prognostic and functional role of microRNAs in acute myeloid leukemia.

  2011cited by this paper
• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

  2011cited by this paper
• Therapeutic advances in acute myeloid leukemia.

  2011cited by this paper
• Genomics of AML: clinical applications of next-generation sequencing.

  2011cited by this paper
• TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

  2011cited by this paper
• DNMT3A mutations in acute myeloid leukemia

  2011cited by this paper
• Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

  2011cited by this paper
• Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

  2011cited by this paper
• Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

  2010cited by this paper
• FLT3 as a therapeutic target in AML: still challenging after all these years.

  2010cited by this paper
• Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951.

  2010cited by this paper
• DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

  2010cited by this paper
• Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

  2010cited by this paper
• Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.

  2010cited by this paper
• High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis

  2010cited by this paper
• Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• "I am older, not elderly," said the patient with acute myeloid leukemia.

  2010influential reference
• DNMT3A mutations in acute myeloid leukemia.

  2010cited by this paper
• The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

  2010cited by this paper
• The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

  2010cited by this paper
• The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

  2009cited by this paper
• Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• High-dose daunorubicin in older patients with acute myeloid leukemia.

  2009cited by this paper
• Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.

  2009cited by this paper
• Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

  2009cited by this paper
• AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

  2009cited by this paper
• Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

  2009cited by this paper
• Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

  2009cited by this paper
• Functional proteomic profiling of AML predicts response and survival.

  2009cited by this paper
• High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

  2009cited by this paper
• New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

  2009cited by this paper
• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

  2008cited by this paper
• Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

  2008cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper
• High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

  2008cited by this paper
• Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

  2008cited by this paper
• Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

  2008cited by this paper
• FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

  2008cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008cited by this paper
• DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

  2007cited by this paper
• Transcriptional dysregulation during myeloid transformation in AML

  2007cited by this paper
• Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

  2007cited by this paper
• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

  2007cited by this paper
• Age and acute myeloid leukemia.

  2006cited by this paper
• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

  2006cited by this paper
• Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

  2006cited by this paper
• FLT3 mutations: biology and treatment.

  2006cited by this paper
• High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

  2006cited by this paper
• Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

  2006cited by this paper

• HEALS-A and GRADES: Novel Histological and Clinical Scales for Assessing Skin Regeneration in Murine Wound Healing Models

  2025cites this paper
• The Combination of Genistein and Imatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines

  2022cites this paper
• The Combination of Genistein andImatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines

  2021cites this paper
• Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center

  2021cites this paper
• Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

  2017cites this paper
• Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia

  2017cites this paper
• RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia

  2017cites this paper
• RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia

  2017cites this paper
• Molecular methodologies and molecular pathology of hematolymphoid neoplasms

  2016cites this paper
• CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome

  2016cites this paper
• Biology and Biomarkers for Wound Healing

  2016cites this paper
• Genetic prognostic factors in acute myeloid leukemia

  2014cites this paper
• The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.

  2013cites this paper
• Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.

  2013cites this paper